Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : firstname.lastname@example.org
|Therapy Name||Paclitaxel + Ramucirumab|
Cyramza (ramucirumab) in combination with paclitaxel is FDA approved for the treatment of patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma (FDA.gov).
|Drug Name||Trade Name||Synonyms||Drug Classes||Drug Description|
|Paclitaxel||Taxol||7-Epipaclitaxel||Antimicrotubule Agent 12 BCL2 Family Inhibitor 6||Taxol (paclitaxel) binds to tubulin to inhibit microtubule disassembly, which results in decreased cell division, and also binds to the anti-apoptotic factor Bcl-2, promoting apoptosis (NCI Drug Dictionary).|
|Ramucirumab||Cyramza||LY3009806||VEGFR2 Antibody 4||Cyramza (ramucirumab) is a monoclonal antibody, which binds and inhibits VEGFR2 (KDR) resulting in decreased angiogenesis (PMID: 24094768). Cyramza (ramucirumab) is approved for gastric and gastroesophageal junction adenocarcinoma, non-small cell lung cancer, hepatocellular carcinoma, and colorectal cancer (FDA.gov).|
|Molecular Profile||Indication/Tumor Type||Response Type||Therapy Name||Approval Status||Evidence Type||Efficacy Evidence||References|
|Unknown unknown||stomach cancer||not applicable||Paclitaxel + Ramucirumab||FDA approved||Actionable||In a Phase III trial that supported FDA approval, treatment with Cyramza (ramucirumab) in combination with Taxol (paclitaxel) increased progression-free and overall survival and improved quality of life compared to treatment with Taxol (paclitaxel) alone in patients with advanced gastric cancer (PMID: 24706672).||24706672 detail...|
|Unknown unknown||gastroesophageal junction adenocarcinoma||not applicable||Paclitaxel + Ramucirumab||FDA approved||Actionable||In a Phase III trial that supported FDA approval, treatment with Cyramza (ramucirumab) in combination with Taxol (paclitaxel) increased progression-free and overall survival and improved quality of life compared to treatment with Taxol (paclitaxel) alone in patients with gastroesophageal junction adenocarcinoma (PMID: 24706672).||24706672 detail...|
|Clinical Trial||Phase||Therapies||Title||Recruitment Status|
|NCT03281369||Phase Ib/II||Atezolizumab + Cobimetinib Atezolizumab + Cobimetinib + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Fluorouracil + Leucovorin + Oxaliplatin Atezolizumab + Linagliptin Atezolizumab + PEGPH20 Atezolizumab + BKT140 Paclitaxel + Ramucirumab Fluorouracil + Leucovorin + Oxaliplatin||A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) (UMBRELLA)||Recruiting|
|NCT03704077||Phase II||Nivolumab Paclitaxel + Ramucirumab Nivolumab + Paclitaxel Nivolumab + Paclitaxel + Relatlimab Nivolumab + Relatlimab||An Investigational Immuno-therapy Study of Relatlimab Plus Nivolumab Compared to Various Standard-of-Care Trherapies in Previously Treated Participants With Recurrent, Advanced or Metastatic Gastric Cance or Gastroesophageal Junction Adenocarcinoma||Withdrawn|
|NCT04205968||Phase II||Fluorouracil + Irinotecan + Leucovorin Paclitaxel + Ramucirumab||Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers||Not yet recruiting|